Pharmacology of acute lung injury

Sadatomo Tasaka, Naoki Hasegawa, Akitoshi Ishizaka

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the anti-inflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS.

Original languageEnglish
Pages (from-to)83-95
Number of pages13
JournalPulmonary Pharmacology and Therapeutics
Volume15
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Acute Lung Injury
Adult Respiratory Distress Syndrome
Vasodilator Agents
Surface-Active Agents
Adrenal Cortex Hormones
Nitric Oxide
Anti-Inflammatory Agents
Pharmacology
Mortality
Therapeutics

Keywords

  • ALI/ARDS
  • Pharmacological treatment
  • Sepsis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

Pharmacology of acute lung injury. / Tasaka, Sadatomo; Hasegawa, Naoki; Ishizaka, Akitoshi.

In: Pulmonary Pharmacology and Therapeutics, Vol. 15, No. 2, 2002, p. 83-95.

Research output: Contribution to journalArticle

Tasaka, Sadatomo ; Hasegawa, Naoki ; Ishizaka, Akitoshi. / Pharmacology of acute lung injury. In: Pulmonary Pharmacology and Therapeutics. 2002 ; Vol. 15, No. 2. pp. 83-95.
@article{28d11fce2c3743faad5ed43d10fde7ea,
title = "Pharmacology of acute lung injury",
abstract = "The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the anti-inflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS.",
keywords = "ALI/ARDS, Pharmacological treatment, Sepsis",
author = "Sadatomo Tasaka and Naoki Hasegawa and Akitoshi Ishizaka",
year = "2002",
doi = "10.1006/pupt.2001.0325",
language = "English",
volume = "15",
pages = "83--95",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacology of acute lung injury

AU - Tasaka, Sadatomo

AU - Hasegawa, Naoki

AU - Ishizaka, Akitoshi

PY - 2002

Y1 - 2002

N2 - The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the anti-inflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS.

AB - The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the anti-inflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS.

KW - ALI/ARDS

KW - Pharmacological treatment

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=0036318639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036318639&partnerID=8YFLogxK

U2 - 10.1006/pupt.2001.0325

DO - 10.1006/pupt.2001.0325

M3 - Article

C2 - 12090781

AN - SCOPUS:0036318639

VL - 15

SP - 83

EP - 95

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 2

ER -